Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer

Table 3 Relationship between hypoxia-inducible factor 1α and clinicopathological factors in patients with gastric cancer

Characteristics	Sample size, n	HIF1α		P
		Low expression (%)	High expression (%)
Gender		93 (66.4)	47 (33.6)
Male	112	76 (67.9)	36 (32.1)	0.474
Female	28	17 (60.7)	11 (39.3)
Age
< 60 yr	67	47 (70.1)	20 (29.9)	0.372
≥ 60 yr	73	46 (63.0)	27 (37.0)
Tumor location
Upper part	57	41 (71.9)	16 (28.1)	0.702
Middle part	34	19 (55.9)	15 (44.1)
Lower part	44	30 (68.2)	14 (31.8)
Total stomach	5	3 (60.0)	2 (40.0)
Tumor size
< 5 cm	57	41 (71.9)	16 (28.1)	0.253
≥ 5 cm	83	52 (62.7)	31 (37.3)
Depth of invasion
T1	5	5 (100.0)	0 (0.0)	0.001
T2	13	12 (92.3)	1 (7.7)
T3	85	60 (70.6)	25 (29.4)
T4	37	16 (43.2)	21 (56.8)
Lymphatic metastasis
0	34	29 (85.3)	5 (14.7)	0.000
1-2	32	24 (75.0)	8 (25.0)
3-6	31	23 (74.2)	8 (25.8)
7-15	37	17 (45.9)	20 (54.1)
≥ 16	6	0 (0.0)	6 (100.0)
Borrmann classification
Type I	16	11 (68.8)	5 (31.2)	0.183
Type II or III	110	76 (69.1)	34 (30.9)
Type IV	11	4 (36.4)	7 (63.6)
Type V	3	2 (66.7)	1 (33.3)
WHO histological classification
Adenocarcinoma	77	55 (71.4)	22 (28.6)	0.725
Signet-ring cell carcinoma	17	12 (70.6)	5 (29.4)
Mucinous adenocarcinoma	8	6 (75.0)	2 (25.0)
Mixed carcinoma	32	20 (62.5)	12 (37.5)
Neuroendocrine carcinoma	6	4 (66.7)	2 (33.3)
Lauren parting
Intestinal type	65	42 (64.6)	23 (35.4)	0.155
Diffuse type	68	44 (64.7)	24 (35.3)
Mixed type	7	7 (100.0)	0 (0.0)
Differentiation grade
Low and middle	107	72 (67.3)	35 (32.7)	0.698
High	33	21 (63.6)	12 (36.4)
Cancer embolus
Yes	51	32 (62.7)	19 (37.3)	0.485
No	89	61 (68.5)	28 (31.5)
Affect neural
Yes	50	30 (60.0)	20 (40.0)	0.230
No	90	63 (70.0)	27 (30.0)
TNM staging
I	10	10 (100.0)	0 (0.0)	0.000
II	49	44 (89.8)	5 (10.2)
III	81	39 (48.1)	42 (51.9)

HIF1α: Hypoxia-inducible factor 1α; WHO: Word Health Organization; TNM: Tumor-node-metastasis.